Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products
April 23, 2022 at 14:59 PM EDT
Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing from an affiliate of R-Bridge Healthcare Fund.
